KAPAKairos Pharma, LTD.vs its industry peers
A metric-by-metric comparison of Kairos Pharma, LTD. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KAPAEsta | $42M#8 | — | 10.1x#11 | — | — | -109.3%#14 | — | -130.0%#8 | — | — | -85.0%#13 | — |
| XLO | $52M#1 | — | 0.7x#3 | 1.2x#2 | 589.9%#1 | 39.8%#4 | -95.9%#4 | -48.5%#4 | — | — | -15.2%#1 | — |
| VBIO | $50M#2 | — | 11.8x#12 | 64.0x#10 | -33.7%#6 | -57.0%#11 | -1012.6%#8 | -209.1%#9 | — | — | -97.1%#15 | — |
| ELTX | $49M#3 | — | 6.2x#10 | 21.2x#8 | -91.9%#9 | 23.8%#5 | -1639.0%#10 | -498.6%#12 | — | — | -83.9%#12 | — |
| PDSB | $48M#4 | — | — | — | — | 8.3%#8 | — | — | -541.6%#6 | — | -26.1%#3 | — |
| HOWL | $47M#5 | — | 2.9x#9 | — | — | 13.7%#6 | — | -373.3%#10 | -229.9%#3 | — | -32.2%#5 | — |
| ANVS | $46M#6 | — | — | — | — | -17.3%#9 | — | — | — | — | -53.6%#8 | — |
| SCYX | $44M#7 | 15.9x#3 | 0.7x#2 | 2.2x#4 | 449.9%#2 | 59.6%#2 | -78.0%#2 | -12.9%#2 | — | 7#1 | -45.1%#7 | — |
| SDEV | $42M#9 | — | 0.3x#1 | 4.3x#6 | -6.4%#5 | -8632.9%#16 | -86.3%#3 | -495.7%#11 | -7.0%#1 | — | -89.6%#14 | 11.5%#1 |
| MCRB | $41M#10 | — | 1.2x#4 | 52.0x#9 | — | 4088.2%#1 | -11910.1%#11 | 16.5%#1 | -72.9%#2 | — | -76.7%#11 | — |
| VERU | $41M#11 | — | 1.4x#6 | 2.4x#5 | 3.6%#3 | 39.9%#3 | -146.6%#5 | -80.1%#5 | -399.3%#5 | — | -31.6%#4 | 0.0%#2 |
| KPTI | $41M#12 | — | — | 0.3x#1 | 0.6%#4 | -156.5%#15 | -62.1%#1 | — | — | — | -70.7%#10 | — |
| ELAB | $39M#13 | — | 2.3x#8 | 65.6x#11 | — | -24.0%#10 | -1304.4%#9 | -46.3%#3 | — | — | -99.7%#16 | — |
| CRVO | $39M#14 | 0.0x#1 | 1.7x#7 | 9.6x#7 | -58.9%#8 | -65.6%#13 | -706.2%#7 | -117.5%#7 | -5165.9%#7 | — | -67.4%#9 | — |
| ATNM | $38M#15 | 3.4x#2 | 1.2x#5 | 419.2x#12 | — | 11.4%#7 | -40274.4%#12 | -111.8%#6 | — | — | -25.9%#2 | — |
| CELU | $37M#16 | — | — | 1.4x#3 | -51.0%#7 | -58.4%#12 | -230.9%#6 | — | -398.1%#4 | — | -41.8%#6 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice